Patents by Inventor Jürgen Wichmann
Jürgen Wichmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230331682Abstract: The invention relates to a compound of formula (I) Wherein A, L, R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 16, 2023Publication date: October 19, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
-
Publication number: 20230322776Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 16, 2023Publication date: October 12, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Erik Jung, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
-
Publication number: 20230145336Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.Type: ApplicationFiled: December 19, 2022Publication date: May 11, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Katrina L. Jackson, Yanke Liang, Moses Moustakim, Morgan Welzel O'Shea, Gesine Kerstin Veits, Jeremy L. Yap, Robert T. Yu, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Bernd Kuhn, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
-
Publication number: 20230002367Abstract: The invention provides a bifunctional compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein said Targeting Ligand, Linker and Degron are as described herein.Type: ApplicationFiled: October 26, 2020Publication date: January 5, 2023Inventors: Delphine GAUFRETEAU, Roman HUTTER, Eleonora JOVCHEVA, Bernd KUHN, Thomas LUEBBERS, Rainer E. MARTIN, Laetitia Janine MARTIN, Barbara Johanna MUELLER, Roger NORCROSS, Fabienne RICKLIN, Philipp SCHMID, Jean-Yves WACH, Juergen WICHMANN, Martin DUPLESSIS, Kiel LAZARSKI, Yanke LIANG
-
Publication number: 20220298145Abstract: The invention provides a novel compound having the general formula (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 8, 2022Publication date: September 22, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, David Stephen HEWINGS, Daniel HUNZIKER, Daniela KRUMMENACHER, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
-
Publication number: 20220298119Abstract: The invention provides a novel compound having the general formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 8, 2022Publication date: September 22, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, David Stephen HEWINGS, Daniel HUNZIKER, Daniela KRUMMENACHER, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
-
Patent number: 10577332Abstract: The present invention relates to compounds of formula I wherein R1? is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tertbutyl, cyclopropyl or CF3; R3 is Cl, F, CF3, methyl, methoxy, isopropyl or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof for use in the treatment of schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: GrantFiled: April 19, 2016Date of Patent: March 3, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Marius Hoener, Juergen Wichmann
-
Patent number: 10556870Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R1?, R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: April 12, 2019Date of Patent: February 11, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Marius Hoener, Juergen Wichmann
-
Publication number: 20190343839Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 17, 2019Publication date: November 14, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Theresa M. BALLARD, Silvia Gatti MCARTHUR, Michael SAXE, Juergen WICHMANN, Thomas WOLTERING
-
Patent number: 10457663Abstract: The present invention relates to compounds of formula I wherein R1? is CH3; R1 is CH3, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, CH3, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropyl-methyl or hydroxy-methyl; R3 is hydrogen, Cl, F, CF3, CH3, isopropyl, methoxy, cyano or cyclopropyl; R4 is hydrogen, CH3, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: GrantFiled: July 30, 2018Date of Patent: October 29, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Marius Hoener, Juergen Wichmann
-
Patent number: 10457644Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R1?, R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: November 19, 2018Date of Patent: October 29, 2019Assignee: Hoffman-La Roche Inc.Inventors: Marius Hoener, Juergen Wichmann
-
Publication number: 20190233379Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R1?, R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: April 12, 2019Publication date: August 1, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Marius HOENER, Juergen WICHMANN
-
Patent number: 10273217Abstract: The present invention relates to compounds of formula I wherein R1? is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, hydroxmethyl, or 2-propyl-2-ol; R3 is Cl, F, CF3, cyano, methyl, methoxy, isopropyl, or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: GrantFiled: March 28, 2018Date of Patent: April 30, 2019Assignee: HOFFMANN-LA ROCHE INC.Inventors: Marius Hoener, Juergen Wichmann
-
Publication number: 20190119218Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R1?, R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: November 19, 2018Publication date: April 25, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Marius HOENER, Juergen WICHMANN
-
Patent number: 10155741Abstract: The present invention relates to compounds of formula I wherein R1? is methyl; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropylmethyl, or hydroxmethyl; R3 is Cl, F, CF3, methyl, methoxy, or cyclopropyl; R4 is hydrogen, methyl, F or Cl; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: GrantFiled: April 17, 2018Date of Patent: December 18, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Marius Hoener, Juergen Wichmann
-
Publication number: 20180339975Abstract: The present invention relates to compounds of formula I wherein R1? is CH3; R1 is CH3, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, CH3, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropyl-methyl or hydroxy-methyl; R3 is hydrogen, Cl, F, CF3, CH3, isopropyl, methoxy, cyano or cyclopropyl; R4 is hydrogen, CH3, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: ApplicationFiled: July 30, 2018Publication date: November 29, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Marius HOENER, Juergen WICHMANN
-
Publication number: 20180297961Abstract: The present invention relates to compounds of formula I wherein R1? is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tertbutyl, cyclopropyl or CF3; R3 is Cl, F, CF3, methyl, methoxy, isopropyl or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof for use in the treatment of schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: ApplicationFiled: April 19, 2016Publication date: October 18, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Marius HOENER, Juergen WICHMANN
-
Patent number: 10092546Abstract: The present invention relates to compounds of formula I wherein R1? is CH3; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tertbutyl, cyclopropyl, hydroxmethyl, or 2-propyl-2-ol; R3 is Cl, F, CF3, methyl, methoxy, isopropyl, cyano or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: GrantFiled: January 9, 2018Date of Patent: October 9, 2018Assignee: Hoffman-La Roche Inc.Inventors: Marius Hoener, Juergen Wichmann
-
Publication number: 20180258066Abstract: The present invention relates to compounds of formula I wherein R1? is methyl; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropylmethyl, or hydroxmethyl; R3 is Cl, F, CF3, methyl, methoxy, or cyclopropyl; R4 is hydrogen, methyl, F or Cl; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: ApplicationFiled: April 17, 2018Publication date: September 13, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Marius HOENER, Juergen WICHMANN
-
Publication number: 20180235971Abstract: The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 25, 2018Publication date: August 23, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Theresa M. Ballard, Silvia Gatti McArthur, Michael Saxe, Juergen Wichmann, Thomas Woltering